← All trials
NCT05330377
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2023
- Primary completion
- May 30, 2027
- Completion date
- May 30, 2032
- First posted
- Apr 15, 2022
- Last posted
- Oct 28, 2022
- Enrollment
- 15
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of KentuckyLead sponsor
- AstellasCollaborator
- University of KentuckyOverall official - principal investigator
- University of KentuckySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.